Christiane Gasperi1, Arthur Melms1, Benedikt Schoser1, Yina Zhang1, Julia Meltoranta1, Valerie Risson1, Laurent Schaeffer1, Bertold Schalke1, Stephan Kröger2. 1. From the Institute for Physiology, Department of Physiological Genomics (C.G., Y.Z., J.M., S.K.), and Friedrich-Baur-Institute (B. Schoser), Ludwig-Maximilians University, Munich; Department of Neurology (B. Schalke), University of Regensburg; Department of Neurology (A.M.), University of Tübingen, Germany; and Laboratory of Molecular Biology of the Cell (V.R., L.S.), University of Lyon, France. A.M. is currently affiliated with the Department of Neurology, University Hospital Erlangen, Germany. 2. From the Institute for Physiology, Department of Physiological Genomics (C.G., Y.Z., J.M., S.K.), and Friedrich-Baur-Institute (B. Schoser), Ludwig-Maximilians University, Munich; Department of Neurology (B. Schalke), University of Regensburg; Department of Neurology (A.M.), University of Tübingen, Germany; and Laboratory of Molecular Biology of the Cell (V.R., L.S.), University of Lyon, France. A.M. is currently affiliated with the Department of Neurology, University Hospital Erlangen, Germany. skroeger@LMU.de.
Abstract
OBJECTIVE: Because the extracellular matrix protein agrin is essential for neuromuscular junction formation and maintenance, we tested the hypothesis that autoantibodies against agrin are present in sera from patients with myasthenia gravis (MG). METHODS: We determined the presence of anti-agrin antibodies in 54 sera from patients with generalized MG using a solid-phase ELISA with purified mini-agrin protein. Thirty of the 54 sera were seronegative for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK), 15 had elevated levels of anti-MuSK, and 9 had elevated levels of anti-AChR autoantibodies. Sixteen sera from healthy volunteers served as control. RESULTS: Five sera with elevated levels of anti-agrin antibodies were identified. The concentration of the antibodies ranged between 0.04 and 0.12 nM. Four of the 5 agrin-positive sera were also positive for anti-MuSK, one was positive for anti-AChR, and 2 had elevated levels of anti-low-density lipoprotein receptor-related protein 4 (LRP4) autoantibodies. Some of the sera stained adult mouse neuromuscular junctions and reacted with native mini-agrin expressed in 293HEK cells. CONCLUSIONS: The results provide evidence for agrin as a novel target protein for autoantibodies in patients with MG. Anti-agrin antibodies were always detected in combination with autoantibodies against MuSK, LRP4, or AChRs, indicating a high incidence of autoantibodies against several neuromuscular proteins in the agrin-positive MG cases.
OBJECTIVE: Because the extracellular matrix protein agrin is essential for neuromuscular junction formation and maintenance, we tested the hypothesis that autoantibodies against agrin are present in sera from patients with myasthenia gravis (MG). METHODS: We determined the presence of anti-agrin antibodies in 54 sera from patients with generalized MG using a solid-phase ELISA with purified mini-agrin protein. Thirty of the 54 sera were seronegative for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK), 15 had elevated levels of anti-MuSK, and 9 had elevated levels of anti-AChR autoantibodies. Sixteen sera from healthy volunteers served as control. RESULTS: Five sera with elevated levels of anti-agrin antibodies were identified. The concentration of the antibodies ranged between 0.04 and 0.12 nM. Four of the 5 agrin-positive sera were also positive for anti-MuSK, one was positive for anti-AChR, and 2 had elevated levels of anti-low-density lipoprotein receptor-related protein 4 (LRP4) autoantibodies. Some of the sera stained adult mouse neuromuscular junctions and reacted with native mini-agrin expressed in 293HEK cells. CONCLUSIONS: The results provide evidence for agrin as a novel target protein for autoantibodies in patients with MG. Anti-agrin antibodies were always detected in combination with autoantibodies against MuSK, LRP4, or AChRs, indicating a high incidence of autoantibodies against several neuromuscular proteins in the agrin-positive MG cases.
Authors: John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor Journal: Muscle Nerve Date: 2017-09-30 Impact factor: 3.217
Authors: Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys Journal: J Neurol Date: 2017-05-17 Impact factor: 4.849
Authors: Michael H Rivner; Siyang Liu; Brandy Quarles; Brandi Fleenor; Chengyong Shen; Jinxiu Pan; Lin Mei Journal: Muscle Nerve Date: 2016-11-29 Impact factor: 3.217
Authors: Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace Journal: JAMA Neurol Date: 2015-06 Impact factor: 18.302